Pharmaceuticals

Biosimilars Market Anticipated to Record Steady Gains, Advancing to $48.52 Billion by 2030

February 12, 2026February 12, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the biosimilars market from 2026–2035 with trusted insights from The Business Research Company

What level of CAGR-driven expansion is anticipated in the Biosimilars Market between 2026 and 2030?

The biosimilars market has demonstrated significant growth in size over recent years. Its value is predicted to increase from $21.85 billion in 2025 to $25.53 billion in 2026, achieving a compound annual growth rate (CAGR) of 16.9%. The expansion observed in the past can be linked to factors such as the increasing prevalence of chronic and autoimmune diseases, the considerable expense of originator biologics, a growing demand for cost-effective therapeutic options, progress in biopharmaceutical research and development, and the evolving healthcare infrastructure in emerging economies.

The biosimilars market is projected for substantial expansion in the coming years. This market is anticipated to reach $48.52 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 17.4%. Factors driving this expansion during the forecast period include the expiry of patents for major biologics, greater integration of biosimilars into oncology and autoimmune treatments, government support through incentives and favorable policies, the enlargement of manufacturing capacities in the Asia-Pacific region, and the increasing collaborations between biopharmaceutical firms and contract manufacturing organizations. Key trends anticipated during this period encompass the development of personalized biosimilars, the production of biologics more economically, the standardization and adherence to regulations, the broadening of nascent markets for biosimilars, and the formation of strategic alliances and partnerships.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2807&type=smp

What Drivers Are Affecting Demand-Supply Dynamics In The Biosimilars Market?

Elevated healthcare costs are projected to drive expansion within the biosimilars market. Healthcare expenditures encompass the collective financial outlay for medical products and services within a defined population or healthcare framework. The biosimilars market contributes to mitigating healthcare spending through the provision of more economical substitutes for costly biologic medications, consequently decreasing treatment expenses for both patients and healthcare infrastructure. As an illustration, data from March 2024, provided by the Health Foundation, a UK-based independent charity and think tank, indicates that total health spending in England for the most recent confirmed year, 2022/23, amounted to £182 billion ($196.78 billion). Although projected health spending is slated to increase to £192 billion ($207.59 billion) by 2024/25, inflationary pressures will lead to a mere 0.6% real-term growth when contrasted with the 2023/24 fiscal year. Consequently, the rise in healthcare expenditures is a key impetus behind the expansion of the biosimilars market.

How Is The Biosimilars Market Organized Into Various Segments?

The biosimilars market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones

2) By Protein Type: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins

3) By Application: Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications

Subsegments:

1) By Monoclonal Antibodies: IgG Biosimilars, Non-IgG Biosimilars

2) By Insulin: Rapid-Acting Insulin Biosimilars, Long-Acting Insulin Biosimilars, Premixed Insulin Biosimilars

3) By Erythropoietin: Epoetin Alfa Biosimilars, Darbepoetin Alfa Biosimilars

4) By Granulocyte-Colony Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars

5) By Other Hormones: Growth Hormones, Hormonal Replacement Therapy Biosimilars

What Trends Are Driving The Growth Trajectory Of The Biosimilars Market?

Leading companies within the biosimilars market are concentrating on creating novel products to secure a competitive advantage. FYLNETRA, a leukocyte growth factor, is prescribed to reduce the occurrence of infections, particularly febrile neutropenia, in individuals with non-myeloid malignancies undergoing myelosuppressive anti-cancer treatments where febrile neutropenia is a significant clinical risk. For example, Amneal Pharmaceuticals Inc., a US pharmaceutical firm, commercially launched FYLNETRA (pegfilgrastim-pbbk) in May 2023. This biosimilar, which references Neulasta, is supplied in a pre-filled single-dose syringe. FYLNETRA addresses neutropenia, a condition characterized by low levels of neutrophils (white blood cells crucial for fighting infection), frequently observed in patients receiving chemotherapy.

Who Are The Prominent Global Companies Shaping The Biosimilars Market Landscape?

Major companies operating in the biosimilars market are Amgen, Novartis AG, Samsung Bioepis Co. Ltd., Viatris, Celltrion Inc., Coherus Biosciences, Eli Lilly and Company, Dr. Reddy’s Laboratories, Roche India Pvt Ltd, Abbott India Limited, Wuxi Biologics, Shanghai Henlius Biotech, Innovent Biologics, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, Bio-Thera, Sandoz Pty Ltd, Apotex Pty Ltd, Cadila Pharmaceuticals, BiosanaPharma, GlaxoSmithKline, AstraZeneca, Bayer, Merck, Boehringer Ingelheim, Sanofi, Fresenius Kabi, Napp Pharmaceuticals, Mundipharma Deutschland GmbH & Co. KG, Geropharm, Valenta, NovaMedica, SynBio, Rani Therapeutics, Johnson & Johnson, Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty)

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Biosimilars Market?

North America was the largest region in the global biosimilars market in 2025. Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Biosimilars Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2807&type=smp

Browse Through More Reports Similar to the Global Biosimilars Market 2026, By The Business Research Company

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795